Literature DB >> 23108773

Secondary sclerosing cholangitis in critically ill patients: model of end-stage liver disease score and renal function predict outcome.

T Voigtländer1, A A Negm, A S Schneider, C P Strassburg, M P Manns, J Wedemeyer, T O Lankisch.   

Abstract

Secondary sclerosing cholangitis in critically ill patients (SSC - CIP) is an underdiagnosed emerging disease. The aim of this study was to characterize clinical features and prognostic factors for mortality in SSC - CIP. This retrospective study included 54 patients who were diagnosed via endoscopic retrograde cholangiopancreatography (ERCP) after cardiothoracic surgery (n = 21), sepsis (n = 13), polytrauma (n = 11), and others (n = 9). In total, 33 patients who either died (n = 27) or needed liver transplantation (n = 6) were compared with surviving patients (n = 21). The model for end-stage liver disease (MELD) score and need for renal replacement therapy were independent risk factors for mortality. Compared with ERCP, accuracy was 30% for ultrasound and 36 % for liver biopsies. As a result of microbiological bile analysis, 28 % of patients required a change in antibiotic treatment. SSC - CIP is frequently a fatal disease. ERCP should be considered in selected patients to establish the diagnosis and hence provide useful clinical information. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23108773     DOI: 10.1055/s-0032-1325733

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  16 in total

Review 1.  Secondary Sclerosing Cholangitis: a Review of Recent Literature.

Authors:  John Brooling; Rolando Leal
Journal:  Curr Gastroenterol Rep       Date:  2017-09

Review 2.  Secondary Sclerosing Cholangitis in Critically Ill Patients: An Underdiagnosed Entity.

Authors:  Pedro Martins; Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2019-07-30

Review 3.  [Diseases and diagnosis of the biliary system : When does the gastroenterologist need the radiologist?]

Authors:  Thomas von Hahn; K I Ringe; A Potthoff
Journal:  Radiologe       Date:  2019-04       Impact factor: 0.635

Review 4.  Update on Sclerosing Cholangitis in Critically Ill Patients.

Authors:  Gabriele I Kirchner; Petra Rümmele
Journal:  Viszeralmedizin       Date:  2015-06-09

Review 5.  Acute Bacterial Cholangitis.

Authors:  Vincent Zimmer; Frank Lammert
Journal:  Viszeralmedizin       Date:  2015-06-11

6.  Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients.

Authors:  Silke Leonhardt; Wilfried Veltzke-Schlieker; Andreas Adler; Eckart Schott; Roland Hetzer; Walter Schaffartzik; Michael Tryba; Peter Neuhaus; Daniel Seehofer
Journal:  Crit Care       Date:  2015-03-31       Impact factor: 9.097

Review 7.  Secondary sclerosing cholangitis in critically ill patients: current perspectives.

Authors:  Hafsteinn O Gudnason; Einar S Björnsson
Journal:  Clin Exp Gastroenterol       Date:  2017-06-23

8.  Secondary Sclerosing Cholangitis in Critically Ill Patients: Clinical Presentation, Cholangiographic Features, Natural History, and Outcome: A Series of 16 Cases.

Authors:  Silke Leonhardt; Wilfried Veltzke-Schlieker; Andreas Adler; Eckart Schott; Dennis Eurich; Wladimir Faber; Peter Neuhaus; Daniel Seehofer
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

9.  NOD2 gene variants confer risk for secondary sclerosing cholangitis in critically ill patients.

Authors:  Christoph Jüngst; Vanessa Stadlbauer; Matthias C Reichert; Vincent Zimmer; Susanne N Weber; Lisa Ofner-Ziegenfuß; Torsten Voigtländer; Walter Spindelböck; Peter Fickert; Gabriele I Kirchner; Frank Lammert; Tim O Lankisch; Marcin Krawczyk
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

10.  Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.

Authors:  Torsten Voigtländer; Jochen Metzger; Holger Husi; Martha M Kirstein; Martin Pejchinovski; Agnieszka Latosinska; Maria Frantzi; William Mullen; Thorsten Book; Harald Mischak; Michael P Manns
Journal:  J Biomed Sci       Date:  2020-01-03       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.